Elia Seguí
Impact in
- Oncology top 5%
- COVID-19 and healthcare impacts
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Infectious Diseases top 10%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
Papers in
- Oncology 25
- COVID-19 and healthcare impacts 12
- Cancer Immunotherapy and Biomarkers 8
- Inflammatory Biomarkers in Disease Prognosis 3
-
- Breast Cancer Treatment Studies 12
- Co-authors
- Francesco Schettini (4 shared papers)Aleix Prat (9 shared papers)Alba Di Leone (1 shared paper)Luisa Carbognin (1 shared paper)Giampaolo Tortora (1 shared paper)Antonio Franco (1 shared paper)Núria Chic (3 shared papers)Giovanna Garufi (1 shared paper)
- Journals
- ESMO Open (8 papers)Annals of Oncology (6 papers)The Lancet Oncology (3 papers)European Journal of Cancer (3 papers)Frontiers in Oncology (2 papers)
- Partner nations
- SpainItalyUnited Kingdom
In The Last Decade
Elia Seguí
43 papers receiving 828 citations
Peers
Comparison fields: 5 of 56
- Oncology 454
- Infectious Diseases 230
- Cancer Research 92
- Neurology 68
- Internal Medicine 9
Countries citing papers authored by Elia Seguí
This map shows the geographic impact of Elia Seguí's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elia Seguí with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elia Seguí more than expected).
Fields of papers citing papers by Elia Seguí
This network shows the impact of papers produced by Elia Seguí. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elia Seguí. The network helps show where Elia Seguí may publish in the future.
Co-authors
The 25 scholars most cited alongside Elia Seguí, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 46 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 153 | |
| 2 | 2021 | 92 | |
| 3 | 2018 | 85 | |
| 4 | 2022 | 67 | |
| 5 | 2021 | 60 | |
| 6 | 2020 | 53 | |
| 7 | 2021 | 42 | |
| 8 | 2021 | 30 | |
| 9 | 2022 | 28 | |
| 10 | 2023 | 25 | |
| 11 | 2022 | 21 | |
| 12 | 2022 | 17 | |
| 13 | 2024 | 17 | |
| 14 | 2021 | 16 | |
| 15 | 2024 | 16 | |
| 16 | 2024 | 15 | |
| 17 | 2023 | 13 | |
| 18 | 2022 | 9 | |
| 19 | 2025 | 9 | |
| 20 | 2020 | 7 |
About Elia Seguí
Elia Seguí is a scholar working on Oncology, Cancer Research, Infectious Diseases, Pulmonary and Respiratory Medicine and Neurology, having authored 46 papers that have together received 838 indexed citations. Recurring topics across this work include COVID-19 and healthcare impacts (12 papers), Breast Cancer Treatment Studies (12 papers), Cancer Immunotherapy and Biomarkers (8 papers), COVID-19 Clinical Research Studies (5 papers), Advanced Breast Cancer Therapies (4 papers), Inflammatory Biomarkers in Disease Prognosis (3 papers), Long-Term Effects of COVID-19 (2 papers) and BRCA gene mutations in cancer (2 papers). The work is most often cited by research in Oncology (454 citations), Infectious Diseases (230 citations), Cancer Research (92 citations), Neurology (68 citations) and Internal Medicine (9 citations). Elia Seguí has collaborated with scholars based in Spain, Italy and United Kingdom. Frequent co-authors include Francesco Schettini, Aleix Prat, Alba Di Leone, Luisa Carbognin, Giampaolo Tortora, Antonio Franco, Núria Chic, Giovanna Garufi, Joan Padrosa and Giovanni Scambia. Their work appears in journals such as ESMO Open, Annals of Oncology, The Lancet Oncology, European Journal of Cancer and Frontiers in Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.